Sample Report
Sample Psychiatric Medication Report
This is a complete Psychiatric Medication Report generated from sample data. Your report will follow the same structure with your personal genetic results.
Sample Data — Not Your Results
Psychiatric Medication Report
February 21, 2026
Based on CPIC psychiatric pharmacogenomics guidelines
My Risk Snapshot
High Pharmacogenomic ImpactYour overall medication genetic risk is High based on current CPIC evidence.
Do this next: Bring this report to your prescriber before starting or changing medications.
In an ER or urgent care visit, this report can speak for you when you can’t.
Your Medication DNA — 90 Second Summary
Top Impact Areas
CYP2C19 — Poor Metabolizer
Affects: escitalopram, citalopram, sertraline, vortioxetine, amitriptyline
What this means: You break down these medications much more slowly than most people.
If you take these meds: Discuss with your prescriber about dose adjustment or alternative medications.
CYP2D6 — Intermediate Metabolizer
Affects: paroxetine, atomoxetine, venlafaxine, nortriptyline, amitriptyline
What this means: You break down these medications slightly differently than average.
If you take these meds: Mention this result when starting new medications in this category.
Gene Impact Overview
Your CYP2C19 result is *2/*2 (Poor Metabolizer).
Your CYP2D6 result is *1/*4 (Intermediate Metabolizer).
When This Report Matters
- ●If you are starting or switching an antidepressant (SSRI/SNRI) — share this report with your prescriber so they can factor in your genetics.
- ●If you are prescribed a tricyclic antidepressant (TCA) — these medications have narrow dosing windows and your genetics may be especially relevant.
- ●If you are starting atomoxetine for ADHD — your CYP2D6 result may affect how quickly you metabolize this medication.
- ●Bring this report to your next psychiatric appointment — these results stay relevant across your lifetime, even as medications change.
Based on CPIC clinical guidelines. This does not replace professional medical advice.
How Your DNA Affects Psychiatric Medications
Depression & Anxiety
ADHD
Compact Decision Table
| Medication | Gene Result | Status | CPIC | Suggestion | Why |
|---|---|---|---|---|---|
| amitriptyline (Elavil) | CYP2C19 *2/*2 + CYP2D6 *1/*4 | Poor Metabolizer / Intermediate Metabolizer | Level A | Consider alternatives or adjusted dosing | Drug levels may build up |
| citalopram (Celexa) | CYP2C19 *2/*2 | Poor Metabolizer | Level A | Consider alternatives or adjusted dosing | Drug levels may build up |
| escitalopram (Lexapro) | CYP2C19 *2/*2 | Poor Metabolizer | Level A | Consider alternatives or adjusted dosing | Drug levels may build up |
| sertraline (Zoloft) | CYP2C19 *2/*2 | Poor Metabolizer | Level A | Consider alternatives or adjusted dosing | Drug levels may build up |
| vortioxetine (Trintellix) | CYP2C19 *2/*2 | Poor Metabolizer | Level A | Consider alternatives or adjusted dosing | Drug levels may build up |
| atomoxetine (Strattera) | CYP2D6 *1/*4 | Intermediate Metabolizer | Level A | Review dosing; monitor for side effects | Slightly slower drug clearance |
| nortriptyline (Pamelor) | CYP2D6 *1/*4 | Intermediate Metabolizer | Level A | Review dosing; monitor for side effects | Slightly slower drug clearance |
| paroxetine (Paxil) | CYP2D6 *1/*4 | Intermediate Metabolizer | Level A | Review dosing; monitor for side effects | Slightly slower drug clearance |
| venlafaxine (Effexor) | CYP2D6 *1/*4 | Intermediate Metabolizer | Level A | Review dosing; monitor for side effects | Slightly slower drug clearance |
Clinician Pocket Summary
High Pharmacogenomic ImpactSignificant: 1|Moderate: 1|Genes tested: 2
| Gene | Diplotype | Phenotype | Key Medications | Suggested Action |
|---|---|---|---|---|
| CYP2C19 | *2/*2 | Poor Metabolizer | escitalopram, citalopram, sertraline, vortioxetine | Consider alternatives or dose adjustment |
| CYP2D6 | *1/*4 | Intermediate Metabolizer | paroxetine, atomoxetine, venlafaxine, nortriptyline | Review dosing; monitor closely |
Scope: This report evaluates CYP2D6 and CYP2C19 only. No additional genes are included.
Based on CPIC psychiatric pharmacogenomics guidelines. Confirm all medication decisions with clinical assessment and therapeutic monitoring.
Detailed Findings
Result: Poor Metabolizer
Diplotype: *2/*2
Confidence: high
Metabolizer Scale
▲ You are here: Poor Metabolizer
Your CYP2C19 genotype (*2/*2) indicates you are a Poor Metabolizer with an activity score of 0.0. You may process escitalopram, citalopram, sertraline, vortioxetine, amitriptyline differently than average. CPIC guidelines recommend discussing dosing adjustments with your prescriber.
- Affected medications: escitalopram, citalopram, sertraline, vortioxetine, amitriptyline
- What to discuss: Discuss with your prescriber before starting or changing these medications.
- Evidence: CPIC Level A
References: PMID:23486447, PMID:25974703, PMID:37032427
Result: Intermediate Metabolizer
Diplotype: *1/*4
Confidence: high
Metabolizer Scale
▲ You are here: Intermediate Metabolizer
Your CYP2D6 genotype (*1/*4) indicates you are an Intermediate Metabolizer with an activity score of 1.0. You may process paroxetine, atomoxetine, venlafaxine, nortriptyline, amitriptyline differently than average. CPIC guidelines recommend discussing dosing adjustments with your prescriber.
- Affected medications: paroxetine, atomoxetine, venlafaxine, nortriptyline, amitriptyline
- What to discuss: Discuss with your prescriber before starting or changing these medications.
- Evidence: CPIC Level A
References: PMID:27997040, PMID:31006110, PMID:37032427
Limitations & Disclaimers
- This report covers CYP2D6 and CYP2C19 only — these are the two genes with the strongest pharmacogenomic evidence for psychiatric medications. Other genes may also play a role.
- CYP2D6 gene duplications and deletions cannot be reliably detected from consumer DNA data. If CYP2D6 metabolism is a clinical concern, laboratory-grade sequencing is recommended.
- Psychiatric medication response depends on many factors beyond genetics, including diagnosis, comorbidities, other medications, lifestyle, and therapeutic monitoring. Genetics is one input among many.
- Do not stop, start, or change any psychiatric medication based solely on this report. All medication changes should be made under the supervision of a licensed prescriber.
- This report is for informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.
- Recommendations are based on current CPIC guidelines and may be updated as new evidence emerges.
Key Terms
Metabolizer Status
How fast or slow your body breaks down a medication. Categories include Poor, Intermediate, Normal, Rapid, and Ultrarapid.
Phenotype
The observable effect of your diplotype on drug metabolism, such as "Poor Metabolizer" or "Normal Metabolizer."
Significant vs. Moderate
Significant means a strong clinical impact is expected. Moderate means an effect is possible but less pronounced.
This is a sample report generated with fictional data for demonstration purposes. Your actual report will reflect your personal genetic results.
What's Inside Your Report
Every Psychiatric Medication Report includes these sections, covering CYP2C19 and CYP2D6 with medications mapped by condition.
Risk Snapshot
Your overall psychiatric medication genetic risk level with significant and moderate finding counts.
90-Second Summary
Top impact areas explained in plain language with the medications affected and when this report matters.
Condition-Based Grouping
Medications organized by condition — Depression & Anxiety, ADHD, Bipolar — with action levels for each.
Decision Table
A compact reference with every affected medication, your gene result, CPIC level, and suggested consideration.
Clinician Pocket Summary
A one-page clinical reference your prescriber can review in under 60 seconds.
Detailed Findings
Full gene-by-gene analysis with diplotype, activity score, affected medications, and CPIC evidence level.
Built on CPIC Guidelines
Every finding in this report cites evidence from the Clinical Pharmacogenetics Implementation Consortium (CPIC) — the same guidelines used by hospitals and pharmacies worldwide. Only Level A (strong) and Level B (moderate) evidence is included.
For educational and informational purposes only. Not a substitute for clinical pharmacogenomic testing or medical advice. See our limitations page for details.
Ready to Unlock Your Psychiatric Report?
Upload your 23andMe or AncestryDNA raw data file and get your personalized psychiatric pharmacogenomic report for $59.